2021
Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A
Li S, Naganawa M, Pracitto R, Najafzadeh S, Holden D, Henry S, Matuskey D, Emery PR, Cai Z, Ropchan J, Nabulsi N, Carson RE, Huang Y. Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 48: 1327-1338. PMID: 33416954, DOI: 10.1007/s00259-020-05149-3.Peer-Reviewed Original ResearchConceptsTest-retest reproducibilityTime-activity curvesBPND valuesNonhuman primatesAbsolute test-retest variabilitySynaptic vesicle glycoprotein 2AHigh brain uptakeNon-displaceable binding potentialExcellent test-retest reproducibilityGray matter areasHealthy human subjectsHigh uptakeTest-retest variabilityDynamic PET scanningTest-retest reliabilityBrain uptakeDistribution volume valuesCentrum semiovaleUrinary bladderOne-tissue compartment modelMaximum SUVPET scanningPET scansTracer uptakeBrain disorders
2015
Preclinical to Clinical Translation of CNS Transporter Occupancy of TD-9855, a Novel Norepinephrine and Serotonin Reuptake Inhibitor
Smith J, Patil D, Daniels O, Ding YS, Gallezot JD, Henry S, Kim K, Kshirsagar S, Martin W, Obedencio G, Stangeland E, Tsuruda P, Williams W, Carson R, Patil. Preclinical to Clinical Translation of CNS Transporter Occupancy of TD-9855, a Novel Norepinephrine and Serotonin Reuptake Inhibitor. The International Journal Of Neuropsychopharmacology 2015, 18: pyu027. PMID: 25522383, PMCID: PMC4368888, DOI: 10.1093/ijnp/pyu027.Peer-Reviewed Original ResearchMeSH KeywordsAdultAniline CompoundsAnimalsBlood Chemical AnalysisBrainHalf-LifeHumansMagnetic Resonance ImagingMaleModels, BiologicalMorpholinesNeurotransmitter Uptake InhibitorsNorepinephrine Plasma Membrane Transport ProteinsPhenyl EthersPiperidinesPositron-Emission TomographyRadiopharmaceuticalsRats, Sprague-DawleyReboxetineSerotonin Plasma Membrane Transport ProteinsSpinal CordSulfidesConceptsReuptake inhibitorsPositron emission tomographyNorepinephrine transporterSerotonin transporterSerotonin reuptake inhibitorsSingle oral doseUnique clinical profileMonoamine reuptake inhibitorsFuture clinical evaluationRat spinal cordNET occupancySERT occupancyClinical profileOral dosePlasma levelsTransporter profilesClinical evaluationSpinal cordTransporter occupancyCNS penetrationHealthy malesPharmacodynamic modelingNorepinephrineEmission tomographyPET studies
2005
Brain imaging of serotonin after recovery from anorexia and bulimia nervosa
Kaye W, Bailer U, Frank G, Wagner A, Henry S. Brain imaging of serotonin after recovery from anorexia and bulimia nervosa. Physiology & Behavior 2005, 86: 15-17. PMID: 16102788, DOI: 10.1016/j.physbeh.2005.06.019.Peer-Reviewed Original ResearchConceptsBulimia nervosaPositron emission tomographyAnorexia nervosaReceptor functionModulation of feedingAge of onsetDegree of efficacyHomogenous presentationSerotonin pathwayGender distributionEmission tomographyBody image distortionBrain functionNew pharmacologyBrain imagingParietal regionsNervosaFood consumptionLines of evidenceSymptomsIllnessAlterationsPsychotherapy approachesPathwayFeeding behaviorSerotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies
Kaye W, Frank G, Bailer U, Henry S, Meltzer C, Price J, Mathis C, Wagner A. Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies. Physiology & Behavior 2005, 85: 73-81. PMID: 15869768, DOI: 10.1016/j.physbeh.2005.04.013.Peer-Reviewed Original ResearchConceptsBulimia nervosaAnorexia nervosaBody image distortionAge of onsetParietal cortical regionsHomogenous presentationSerotonin alterationsLimbic structuresSerotonin pathwayGender distributionCortical regionsBrain functionNew pharmacologyNervosaFood consumptionIllnessSymptomsRecent brainAlterationsRecent studiesPsychotherapy approachesBehavioral inhibitionAnxietyFeeding behaviorHedonic aspects